Announced
Financials
Tags
United States
Pharmaceuticals
Friendly
Single Bidder
Cross Border
Majority
Private
Pending
biopharmaceuticals
Acquisition
Synopsis
Boehringer Ingelheim, a research-driven biopharmaceutical company, agreed to acquire Avexxa Biologics, a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology research to develop the next generation of precision medicines designed to revolutionize cancer treatments. Financial terms were not disclosed. “The acquisition of Abexxa bolsters our commitment to tumor-antigen discovery and new ways of targeting intracellular antigens. Their cutting-edge know-how and technologies for antigen discovery and novel antibody generation strongly complement the current approaches we have been applying successfully to enable immune-targeting of cancer cells,” Clive R. Wood, Boehringer Ingelheim Senior Vice President.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.